ArticleInternational journal of clinical and experimental pathology2018
Ube2s expression is elevated in hepatocellular carcinoma and predicts poor prognosis of the patients.
Article in International journal of clinical and experimental pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 6 citations in OpenAlex.
- Key oncogenes and candidate drugs for hepatitis-B-driven hepatocellular carcinoma progression.Discover oncology · 2025Article
- Diverse roles of UBE2S in cancer and therapy resistance: Biological functions and mechanisms.Heliyon · 2024Review
- UBE2S interacting with TRIM28 in the nucleus accelerates cell cycle by ubiquitination of p27 to promote hepatocellular carcinoma development.Signal transduction and targeted therapy · 2021Article
- UBE2C is a Potential Biomarker for Tumorigenesis and Prognosis in Tongue Squamous Cell Carcinoma.Diagnostics (Basel, Switzerland) · 2020Article
- A Key mRNA-miRNA-lncRNA Competing Endogenous RNA Triple Sub-network Linked to Diagnosis and Prognosis of Hepatocellular Carcinoma.Frontiers in oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ube2s belongs to the ubiquitin-conjugating (E2) enzyme family of the ubiquitin system. Expression and function of Ube2s in human malignancies was largely unknown. Here we report our investigation of Ube2s expression in human non-tumor liver and hepatocellular carcinoma tissues using immunohistochemistry. Ube2s expression was detected in nuclear and cytoplasm. The positive rate of Ube2s in normal liver tissues was 19.2% (5/26). The positive rate of Ube2s expression in liver tissues with hepatocirrhosis (33.3% (6/18)) was higher than that in normal liver tissues (P<0.05). Ube2s expression in hepatocellular carcinoma (59.1% (39/66)) was higher than that in normal liver tissues and liver tissues with hepatocirrhosis (P<0.05). There were 35 cases (53.0%) showing nuclear expression, 21 cases (31.8%) showing cytoplasm expression, 17 cases (25.8%) showing both nuclear and cytoplasm expression, 18 cases (27.3%) showing only nuclear expression and 4 cases (6.1%) showing only cytoplasm expression in hepatocellular carcinoma tissues. Ube2s expression was significantly associated with higher AFP levels (>100 ng/ml), advanced TNM stages (II+III), higher ABCL stages (B+C) in hepatocellular carcinoma (P<0.05). Kaplan Meier analysis showed that Ube2s expression was significantly associated with shorter survival time of patients (
Indexed as
Identifiers
31938165PMC6958058W3027041221What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.